

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* <u>Tan Meng Dong (James)</u> (Last) (First) (Middle) 6 EU TONG SEN STREET #08-13 (Street) SINGAPORE 059817 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>EUDA Health Holdings Ltd [EUDA]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) <input type="checkbox"/> Other (specify below) <input type="checkbox"/>
	3. Date of Earliest Transaction (Month/Day/Year) 11/17/2022	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Ordinary Shares	11/17/2022		J		2,776,000	A	(1)	2,776,000	D	
Ordinary Shares								2,141,250	I	See Footnote(2)
Ordinary Shares	11/24/2021		J		3,000	A	(3)	3,000	D	
Ordinary Shares	11/24/2021		P		292,250	A	(4)	292,250	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Warrants	\$11.5	11/24/2021		P		292,250		(5)	(6)	Ordinary shares	146,125	(4)	292,250	D	
Rights	(7)	11/24/2021		P		292,250		(7)	(7)	Ordinary shares	29,225	(4)	292,250	D	

Explanation of Responses:

- The securities reported here were received from Mr. Tan's through his redemption of 8i Capital Limited's and 8i Enterprises Pte Ltd.'s holdings in Watermark Developments Limited at the closing of EUDA Health Holdings Limited's business combination with EUDA Health Limited. The total capital contribution that Mr. Tan invested was \$400,000 prior to redemption.
- The securities reported herein are held by 8i Holdings 2 Pte. Ltd. and may be deemed to be indirectly beneficially owned by Mr. Meng Dong (James) Tan. Mr. Tan disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein, and this report shall not be deemed an admission that such person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
- The shares were transferred to Mr. Meng Dong (James) Tan from 8i Holdings 2 Pte. Ltd.
- The reporting person acquired 292,250 units consisting of ordinary shares, warrants and rights at a purchase price of \$10.00 per share.
- The warrants become exercisable on the later of (i) the completion of the registrant's initial business combination and (ii) 12 months from the closing of the registrant's initial public offering.
- The warrants expire 5 years after the completion of the registrant's initial business combination or earlier upon redemption or liquidation, as described in the registrant's prospectus filed with the SEC.
- The rights convert automatically into ordinary shares at the completion of the registrant's initial business combination.

/s/ Meng Dong (James) Tan 11/25/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.